Flagler Health has raised $50 million in Series B funding as the healthcare technology company looks to expand its artificial intelligence platform across the U.S. musculoskeletal care market.
The round was led by Bessemer Venture Partners, with participation from SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Ventures, and Offscript. The financing brings Flagler Health’s total capital raised to $63 million.
Rather than focusing on a single administrative task, Flagler is building an AI-driven operational layer intended to work across the patient lifecycle, including referrals, scheduling, patient engagement, care management, prior authorization, billing, and communications.
The New York-based company says it has expanded to thousands of providers across more than 36 states in less than three years. Its next challenge will be demonstrating that the same model can work at substantially greater scale across a highly fragmented healthcare market.
Building AI Into the Operating Layer of MSK Clinics
Flagler’s approach differs from many healthcare AI products that operate as standalone applications or focus primarily on clinical documentation.
The company integrates its technology into providers’ existing electronic medical record (EMR) systems, with the goal of automating work in the background rather than requiring clinicians to adopt another interface. Flagler says practices can deploy its products without additional portals or logins.
Its current technology stack provides a clearer picture of what the company means by an AI operating system.
Flagler offers AI-assisted revenue cycle management for prior authorization and billing, a 24/7 AI call center, patient engagement tools, practice analytics, care management, and automated referral processing. For inbound e-fax referrals, for example, an AI agent can process the referral and move the patient toward scheduling rather than leaving the document in a manual administrative queue.
The platform is also modular. Healthcare organizations can introduce individual components before expanding into other parts of the system, potentially lowering the barrier to deploying automation across an existing practice.
This broader approach reflects an increasingly important direction for healthcare AI. The opportunity is moving beyond helping employees perform individual tasks faster toward software capable of coordinating multiple operational processes around the patient.
Flagler’s Origins in Musculoskeletal Care
Flagler was founded by CEO Albert Katz, Chief Medical Officer Dr. Leon Anijar, and Chief Technology Officer Will Hu.
Katz’s connection to the problem predates the company. Before founding Flagler, he served as CFO of Spine and Wellness Centers of America, a multidisciplinary musculoskeletal clinic in Florida. That experience exposed him to many of the administrative and financial challenges the company is now attempting to automate.
Flagler initially developed technology around remote patient monitoring and chronic care management before expanding deeper into practice operations. Its platform is now designed to coordinate both clinical and administrative activities rather than treating them as separate systems.
The company says its AI has been trained using a large dataset of musculoskeletal patients and can support workflows spanning triage, care management, billing, and patient communications.
Flagler reports that its platform generates an average of $164,000 in additional annual revenue per provider, while 87% of participating patients report improvements in areas including pain, mobility, sleep, or mood. These are company-reported figures and will become increasingly important to validate as deployments expand into larger and more varied healthcare organizations.
Why Musculoskeletal Care Is a Major Target for AI
The scale of the MSK market helps explain the investor interest.
Musculoskeletal disorders encompass conditions affecting bones, joints, muscles, and connective tissues and remain among the most common causes of chronic pain and disability. National Institutes of Health-linked research has estimated that roughly one in two U.S. adults has experienced a musculoskeletal condition, creating significant healthcare costs as well as lost productivity.
Care can also involve numerous specialties, including primary care physicians, physical therapists, physiatrists, rheumatologists, orthopedic surgeons, pain specialists, and other providers. That creates a large number of handoffs, referrals, authorizations, follow-ups, and billing events surrounding a single patient.
Those administrative layers make MSK an interesting environment for AI systems capable of coordinating workflows rather than simply generating text.
Flagler argues that this is where much of the potential economic value lies. If AI can automatically convert referrals into appointments, identify patients requiring follow-up, manage routine communications, support prior authorizations, and reduce billing errors, the technology could affect both the cost of operating a clinic and how much time clinicians spend on non-clinical work.
The Bigger Opportunity for Healthcare AI
The $50 million Series B gives Flagler considerably more capital to test whether its model can move from successful individual deployments toward becoming infrastructure used across larger healthcare networks.
That transition will matter.
Healthcare has already become one of the most active markets for vertical AI, but much of the first generation of adoption has centered on relatively narrow applications such as ambient documentation, medical transcription, coding, and patient messaging.
The emerging opportunity is more ambitious: AI systems that can coordinate multiple administrative and clinical workflows while remaining connected to the underlying systems of record.
Flagler is effectively betting that the EMR does not need to be replaced for healthcare operations to become more autonomous. Instead, an AI layer can sit around the existing infrastructure and increasingly handle the work that happens between patient encounters.
If that model proves scalable, the implications extend beyond musculoskeletal medicine. Similar operational bottlenecks exist throughout healthcare, suggesting that the longer-term competition may not simply be over which company builds the best healthcare AI assistant, but which platforms can reliably automate entire layers of healthcare operations.
For Flagler Health, the Series B provides the capital to find out whether that transition can happen first in one of the largest and most operationally complex areas of American medicine.
